Synopsis

Source of validity: Scientific
Rating (out of 5): 4

Marine lipids, primarily in the form of omega-3 polyunsaturated fatty acids (notably EPA and DHA found in fish oils), have substantial scientific evidence supporting their use for cardiovascular health, including the management and prevention of “heart weakness” (a non-specific but often-used term for heart failure or compromised cardiac function). Numerous randomized controlled trials (RCTs) and meta-analyses have shown that regular intake of marine lipids can lower triglyceride levels, reduce blood pressure slightly, and exert anti-inflammatory and anti-arrhythmic effects. Notably, the GISSI-Prevenzione trial and the more recent REDUCE-IT trial demonstrated that omega-3 supplementation reduced the risk of adverse cardiovascular events in specific populations.

Guidelines from major health organizations such as the American Heart Association recommend the consumption of fatty fish or marine lipid supplements for individuals with existing cardiovascular disease. The evidence is strongest for secondary prevention (preventing further events in people with established heart disease) rather than for the general population. While the overall effect sizes are modest, omega-3 fatty acids are widely accepted as a beneficial adjunct to standard therapy in heart disease. However, they are not a replacement for other proven interventions such as medication, lifestyle modification, or surgical procedures when indicated. Thus, the use of marine lipids to support heart health is primarily justified by robust scientific evidence, especially in at-risk or already affected individuals.

More about marine lipid
More about Heart (weakness)

Other ingredients used for Heart (weakness)

Other health conditions supported by marine lipid

Products containing marine lipid